Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’s NHS Foundation Trust, London, UK, discusses results from the MAJIC-PV trial (ISRCTN61925716) of ruxolitinib vs best available therapy (BAT) for the treatment of hydroxyurea intolerant/resistant polycythemia vera (PV). Complete response (CR) and event-free survival (EFS) were significantly increased in the ruxolitinib group compared to the BAT group. A decrease in JAK2V617F allele fraction also correlated with increased EFS. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.